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Objective To compare the prescription of drugs in women over
a period from 2 years before until 3 months after pregnancy,
regarding the type of drugs used and the fetal risk.
Design A cohort study based on pharmacy records of women
giving birth to a child between 1994 and 2003.
Setting The study was performed with data from the InterAction
database, containing prescription-drug-dispensing data from
community pharmacies.
Population The study population included 5412 women for whom
complete pharmacy records were available.
Methods Drugs were classified into three categories: (1) drugs for
chronic conditions, (2) drugs for occasional use and (3) drugs for
pregnancy-related symptoms and also classified according to the
Australian classification system.
Main outcome measures The prescription rate was calculated as
the number of women per 100 women who received one or more
prescriptions for a given drug within a specified time period.
Results About 79.1% of the women received at least one
prescription during pregnancy. The prescription rate for most
drugs for chronic diseases and for occasional use decreased during
pregnancy, whereas, as expected, the prescription rate for
pregnancy-related drugs increased. During the first trimester of
pregnancy, 1.7% of all drugs prescribed for chronic conditions and
2.3% of the occasional drugs were classified as harmful.
Conclusions The increase in prescription rate during pregnancy is
caused by an increase in prescription rate of drugs for pregnancy-
related symptoms. The prescription of harmful drugs is more
commonly associated with drugs for occasional use rather than
with drugs for chronic conditions. Therefore, a more cautious
prescribing of drugs to healthy women in the fertile age is
necessary.
Keywords Drug utilisation, fetal risk classification, pregnancy,
prescription rate, register based.
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Introduction
Since the teratogenic risk of most drugs is still undetermined,
it is important to monitor drug use regularly among pregnant
women. Drug-utilisation studies reveal that most women use
drugs during pregnancy, with estimations varying from 441 to
99%.2 However, comparison is difficult because of differences
in study design. Interviews or prescription databases may be
used for collecting drug-use data, and the type of drugs stud-
ied may or may not include over-the-counter (OTC) drugs
such as vitamins, iron and analgesics. Most studies found an
increasing trend in drug use during pregnancy.2–7
Drug use cannot be always avoided during pregnancy. For
women with certain chronic medical conditions such as epi-
lepsy, diabetes, inflammatory bowel disease and asthma, the
use of drugs is essential, and benefits for mother and child
may well outweigh the teratogenic risk of the drug.8,9 Other
nonchronic diseases related or unrelated to the pregnancy
may require medical treatment. Most studies do not distin-
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prescribed. Therefore, it is not clear to what extent changes in
drug use among pregnant women can be explained by
chronic, occasional or pregnancy-related drug use.
The aim of this study was to compare the prescription of
drugs in pregnant women, with respect to the type of drugs
and the fetal risk before, during and after pregnancy.
Methods
This study was performed with the InterAction database
(IADB), which contains data on prescriptions dispensed
from community pharmacies in the Netherlands. The IADB
includes all prescription drugs from an estimated popula-
tion of 220 000 from 1994 to 1999 and was expanded to
approximately 450 000 since 1999.10,11 Registration is irre-
spective of health insurance and is considered representative
for the general population. Each prescription record con-
tains information about the drug, date of dispensing, quan-
tity dispensed, dose regimen and the prescribing physician.
The indication for the prescription is not known. All the
drugs are coded according to Anatomical Therapeutic Chem-
ical (ATC) classification.12 Each patient has a unique (anon-
ymous) identifier; date of birth and gender of patients are
known. Due to a high patient–pharmacy commitment in
the Netherlands and sophisticated pharmacy software, the
medication records for each patient are virtually complete.13
The IADB does not include OTC drugs and drugs dispensed
during hospitalisations.
To identify mothers, all children born between 1 January
1994 and 1 January 2004 were selected from the database. For
each child within the IADB, the female person 15–50 years
older than the child with the same address code was consid-
ered to be the mother, providing there were no other female
persons 15–50 years older with the same address code. Using
this method, 65% of the mothers could be identified. Valida-
tion of this method is described in detail by Schirm et al.14
Because only the child’s birth date is known, the theoretical
conception date was determined as the date of birth minus
273 days (i.e. 9 months). Between 1 January 1994 and 1 Jan-
uary 2004, 10 261 women were identified, with a total of
13 894 pregnancies. To rule out the influence of previous
pregnancies, we included only the first pregnancy, as regis-
tered in the database, for which complete pharmacy records
were available in the IADB from 2 years before the theoretical
conception date until 3 months after delivery. According to
these criteria, 5501 women were included. To avoid misclas-
sification of medication use, we subsequently excluded
women who gave birth to twins (n = 87) or triplets (n = 2)
because the gestation period in twin and triplet pregnancies is
more likely to be shorter than in singleton pregnancies. Thus,
for the final analysis, pharmacy data for 5412 women were
used. To allow direct comparisons of prescription rates over
time, the whole study period of 3 years was divided into 12
periods of 13 weeks (trimesters). The 12 trimesters were num-
bered as can be seen in Figure 1.
We ordered drugs that were commonly prescribed into
three mutually exclusive categories: (1) drugs for chronic
conditions, (2) drugs for occasional and short-time use and
(3) drugs for pregnancy-related symptoms. Drugs and drug
groups belonging to these three categories are listed in
Table 1. Drugs for chronic conditions are not necessarily
taken on a chronic basis but can also be taken during episodes
when the disease surfaces. The drugs were also classified based
on the Australian risk classification for pregnancy (Table 2).15
Categories D and X were combined because for both catego-
ries, the use of drugs during pregnancy is clearly contraindi-
cated and only one drug was classified as X (isotretinoine,
D10BA01). The three B categories were combined for statis-
tical purposes. Drugs that were not classified according to the
Australian classification system were categorised as B because
their fetal risk was obviously unknown.
Per trimester, we counted the number of specific drugs
prescribed to individual women, excluding contraceptives.
If a specific drug was prescribed twice during a trimester, it
was counted only once. In addition, prescriptions covering
more than one trimester were counted only in the trimester in
which they were dispensed. The prescription rate was calcu-
lated as the number of women per 100 women who received
one or more prescriptions for a given drug or drug class
within one trimester or otherwise specified time period.
Prescription rates were tested in SPSS 12.0.2 for Windows
(Chicago, USA) over the 3-year study period and the preg-
nancy period, using the chi-square test for trend.
Results
The mean age at birth of the 5412 mothers included was 29.6
years (range 15–49 years). During the 3-year study period, they
received a total of 78 944 drugs, excluding contraceptives, of
Figure 1. Prescription rate for all prescriptions and the mean number of
drugs dispensed among women with at least one prescription. Trimester
–8 to –5 represents the second year before pregnancy, trimester –4 to
–1 represents the first year before pregnancy. The period between the
dotted lines (trimester 1–3) is the pregnancy period, and trimester 4 is
the period after pregnancy.
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which 12 407 drugs were dispensed during pregnancy. Over-
all, 5236 women (96.7%) received at least one prescription
drug during the 3-year study period and 4280 (79.1%)
received at least one prescription drug during their preg-
nancy. Figure 1 presents the prescription rates per trimester
for all drugs, excluding contraceptives. In the 2 years before
pregnancy, the prescription rate was constant, approximately
43 per 100 women. The average number of drugs per trimes-
ter among women who were prescribed drugs was two (range
1–17). The prescription rate increased from 43.6 per 100
women in the first trimester to 49.3 and 60.8 per 100 women
in the second and third trimester of pregnancy. During preg-
nancy, the mean number of prescription drugs per trimester
among women who were prescribed drugs was approximately
the same as before pregnancy (1.9).
During the 3-year study period, 865 different drugs
(based on ATC code) were prescribed to our study popula-
tion, while during the pregnancy period, 470 different drugs
were prescribed. The drugs categorised in Table 1 accounted
for 57.3% of all the different drugs prescribed and for
81.9% of all prescriptions during the 3-year study period. For
the pregnancy period, these were 65.7 and 89.1%, respectively.
The prescription rates per trimester for the drugs listed in
Table 1 are reported in Appendix 1. A graphical reproduction
of the prescription patterns for certain drug groups of the
three categories is shown in Figures 2–4.
A clear decrease in prescription rate in pregnancy was seen
for antidepressants and antipsychotics (N06A/N05A), anti-
migraine drugs (N02C; Figure 2), anti-inflammatory and
antirheumatic drugs (M01). The prescription rates for anti-
epileptics (N03A; Figure 2), antiasthmatics (R03) were nearly
constant during pregnancy. There seems to be an increase in
prescription rate for insulins (A10; Figure 2), but this was not
statistically significant.
Table 1. Categorisation of drugs and drug groups included in this study, according to their ATC code
Categories ATC code
Category I: Drugs for chronic conditions
Drugs used in diabetes A10
Corticosteroids, dermatological preparations D07
Corticosteroids for systemic use H02
Thyroid therapy H03
Anti-inflammatory and antirheumatic products M01
Antimigraine medication N02C
Antiepileptics N03A
Antipsychotics N05A, excl. N05AB04
Antidepressants N06A
Antiasthmatics R03
Category II: Drugs for occasional and short-time use
Antispasmodic and anticholinergic agents and propulsives A03, excl. A03FA01
Antidiarrhoeals, intestinal anti-inflammatory/anti-infective agents A07
Antifungals for dermatological use D01
Emollients and protectives D02
Antibiotics and chemotherapeutics for dermatological use D06
Antiacne preparations D10
Antibacterials for systemic use J01
Analgesics and antipyretics N02B
Anxiolytics N05B
Hypnotics and sedatives N05C
Antiparasitic products, insecticides and repellents P
Antihistamines for systemic use R06, excl. R06AD and R06AE
Ear, eye, nose and throat preparations S02, S03, S01, R01, R02A, R05
Category III: Pregnancy-related drugs
Antacids A02A
Antiemetics A03FA01, A04A, N05AB04, R06AD, R06AE
Laxatives A06
Iron preparations B03A
Folic acid and derivatives B03B
Gynaecological anti-infectives and antiseptics G01
Gonadotrophins and other ovulation stimulants G03G
The drug categories are mutually exclusive.
Drug prescription patterns in pregnancy
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The prescription rates of drugs for occasional use generally
showed a decrease during pregnancy, followed by an increase
after delivery. For antibiotics (J01; Figure 3), there was
a decrease in prescription rate in the first trimester in preg-
nancy but an increasing pattern in the second and third tri-
mester. For antispasmodic and anticholinergic agents (A03)
and for antihistamines for systemic use (R06), there was a
decrease in prescription rate during pregnancy. For analgesics
(N02B, Figure 3), hypnotics and anxiolytics (N05C/N05B)
and for ear, eye, nose and throat preparations (S02, S03,
S01, R01, R02A, R05; Figure 3), there was a decreasing trend
during the 3-year period but constant rates during pregnancy.
As expected, the prescription patterns of drugs for pregnancy-
related symptoms showed an increase during pregnancy. For
folic acid and derivatives (B03B) and for antiemetics (A03FA01,
A04A, R06AD, R06AE; Figure 4), the highest rates can be seen
in the first trimester. Iron preparations (B03A), antacids
(A02A; Figure 4) and gynaecological anti-infectives (G01;
Figure 4) were most prescribed in the second and third tri-
mester in pregnancy. The prescription of laxatives (A06) was
highest after pregnancy. Ovulation stimulants (G03G) were
most prescribed before pregnancy, with a prescription rate of
4.2 per 100 women.
Figures 5–7 show the distribution of the fetal risk classifi-
cation of the prescribed drugs. In these figures, we included
only the drugs that were ordered in the three categories ac-
cording to Table 1. The corresponding numbers can be found
in Appendix 2. As previously described, there was a clear
decrease in the total number of prescribed drugs for chronic
conditions (Figure 5) and for occasional and short-time use
(Figure 6) during pregnancy. This decrease was in contrast
with the number of prescribed drugs for pregnancy-related
Table 2. Risk classification based on the Australian risk classification15 and as used in this study
Category Description Fetal risk classification in this study
A Drugs that have been taken by a large number of pregnant women and
women of childbearing age, without any proven increase in the
frequency of malformations or other direct or indirect harmful effects
on the fetus having been observed.
Safe
B Drugs that have been taken by only a limited number of pregnant women
and women of childbearing age, without an increase in the frequency of
malformation or other direct or indirect harmful effects on the human fetus
having been observed. Studies in animals have not shown evidence of an
increased occurrence of fetal damage or have shown evidence of an
increased occurrence of fetal damage, of which the significance is
considered uncertain in humans.
Undetermined
C Drugs that, owing to their pharmacological effects, have caused or may be
suspected of causing harmful effects on the human fetus or neonate,
without causing malformations. These effects may be reversible.
Potentially harmful
D/X Drugs that have caused or suspected to have caused or may be expected
to cause an increased incidence of human fetal malformations or
irreversible damage. These drugs may also have adverse pharmacological effects.
Harmful
Figure 3. Prescription patterns for certain drugs for occasional and short-
time use in the period from 2 years before pregnancy until 3 months after
delivery. The dots represent the prescription rate per trimester for the
specific drug class. The period between dotted lines is the pregnancy
period. Categorisation of drug groups according to Table 1: antibacterials
for systemic use (J01), analgesics and antipyretics (N02B) and ear, eye,
nose and throat preparations (S02, S03, S01, R01, R02A, R05).
Figure 2. Prescription patterns for certain drugs for chronic conditions
in the period from 2 years before pregnancy until 3 months after delivery.
The dots represent the prescription rate per trimester for the specific drug
class. The period between dotted lines is the pregnancy period. Catego-
risation of drug groups according to Table 1: drugs used in diabetes (A10),
antimigraine medication (N02C) and antiepileptics (N03A).
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symptoms, which showed a large increase during pregnancy,
as shown in Figure 7. When taking all categories together,
81.7% of all drugs prescribed during pregnancy were classified
as A, 10.9% as B, 6.3% as C and 1.1% as D or X. For the drugs
prescribed during the first trimester, these percentages were
70.9, 16.5, 10.2 and 2.4, respectively. However, when we
investigated the distribution of the prescribed drugs per cat-
egory (chronic, occasional or pregnancy related), large differ-
ences are observed.
In the first trimester, only 50.4% of the prescribed drugs for
chronic diseases were considered safe (A), 30.8% were poten-
tially harmful (C) and 1.7% were classified as harmful (D or
X). During pregnancy, the proportion of class A drugs
increased to 67% in the third trimester and the proportion
of drugs classified as C decreased to less than 15%. The pro-
portion of harmful drugs was constant (1.9% in the third
trimester). After pregnancy, the proportion of potentially
harmful and harmful drugs increased to 45%.When we inves-
tigated the prescribed drugs for occasional and short-time
use, 60.8% of the drugs in the first trimester were classified
as safe, 7.8% as potentially harmful and 2.3% as harmful.
During pregnancy, the proportion of drugs classified as A
increased to over 70% in the second and third trimester.
The proportion of harmful drugs decreased to 0.4% in the
third trimester. The majority of the drugs prescribed for preg-
nancy-related symptoms in the first trimester were classified
as safe, 2.1% as potentially harmful and 2.9% as harmful.
In the second and third trimester of pregnancy, 97.6% of
the drugs prescribed for pregnancy-related symptoms were
classified as A, 1% as C and 0.2% as D or X.
Discussion
A clear change in drug prescription patterns is visible among
pregnant women in the Netherlands. Drugs for chronic con-
ditions and for occasional and short-time use were prescribed
less during pregnancy, while at the same time, an increased
prescribing of drugs for pregnancy-related symptoms was
seen. For all three categories, the proportion of drugs classi-
fied as safe increased during pregnancy compared with the
period before and after pregnancy.
The prescription rate covering the 3-year study period was
very high, with 97 per 100 women receiving at least one pre-
scription drug. The high prescription rate may reflect the
Figure 4. Prescription patterns for certain drugs for pregnancy-related
symptoms in the period from 2 years before pregnancy until 3 months after
delivery. The dots represent the prescription rate per trimester for the
specific drug class. The period between dotted lines is the pregnancy
period. Categorisation of drug groups according to Table 1: antacids
(A02A), gynaecological anti-infectives and antiseptics (G01) and
antiemetics (A03FA01, A04A, N05AB04, R06AD and R06AE).
Figure 5. Total number of prescription drugs for chronic conditions
(only the prescribed drugs that were categorised as drugs for occasional
and short-time use as presented in Table 1were counted) per trimester
and the distribution of these drugs according to the pregnancy risk
classification.
Figure 6. Total number of prescription drugs for occasional and short-
time use (only the prescribed drugs that were categorised as drugs for
occasional and short-time use as presented in Table 1 were counted)
per trimester and the distribution of these drugs according to the
pregnancy risk classification.
Figure 7. Total number of prescription drugs for pregnancy-related
symptoms (only the prescribed drugs that were categorised as drugs for
occasional and short-time use as presented in Table 1 were counted) per
trimester and the distribution of these drugs according to the
pregnancy risk classification.
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origin of our study population. To be included in the pre-
scription database, a person had to purchase at least one pre-
scription drug at a participating pharmacy since 1994. In our
population, the prescription rate during pregnancy, including
vitamins and iron, was 79%. This percentage is somewhat
higher than found in a Dutch cohort of women with a low-
risk pregnancy (76.5% of the women attending a gynaecol-
ogist and 57.4% of the women attending a midwife used
medications during pregnancy), but in the latter study, iron
supplements were excluded.16 The prescription rate in this
study was high compared with register-based studies in
Denmark (44.2%, excluding iron and vitamins),1 Finland
(46.2%)17 and USA (64%, excluding vitamins and miner-
als).18 Higher prescription rates during pregnancy were found
in the South West of France (99%, including iron and vita-
mins)2 and in Germany (96.4 and 85.2%, including and
excluding vitamins, respectively).4 Several explanations can
be given for the differences in prescription rates. The Danish
study used a database that did not include prescribed drugs
that were not refunded, such as benzodiazepines, many anal-
gesics and antacids, explaining the lower prescription rates.
Cultural prescribing differences might also play a role in these
variations.
Except for drugs used in diabetes, most drugs for chronic
conditions were prescribed less during pregnancy. In the
trimester after pregnancy, the prescription rate increased but
not to the pre-pregnancy level. Low prescription rates shortly
after pregnancy are most likely a result of breastfeeding. For
some drugs, such as antidepressants and antipsychotics and
antiepileptics, the decrease in prescription rate started before
pregnancy. This decrease may indicate precautionary meas-
ures by women planning pregnancy, as the safety of these
drugs is not established. Several studies have associated the
use of antidepressants with adverse pregnancy outcomes such
as spontaneous abortions, low birthweight and gestational
age.19,20 From our data, it is not possible to infer whether
the decreases are physician driven or woman driven. As the
indication for prescription is not known, the possible adverse
effects of stopping some of these medications is not known.
The prescription rate of antimigraine medication decreased
in the second and third trimester of pregnancy, which might
be a consequence of less migraine attacks during pregnancy
or the use of other analgesics such as paracetamol. Anti-
inflammatory and antirheumatic drugs were also rarely pre-
scribed in pregnancy: the use of these drugs is contraindicated
in pregnancy and moreover, rheumatic disease activity im-
proves in most women during pregnancy.21
The prescription of most drugs for occasional and short-
time use decreased during pregnancy. The increase in the
prescriptions for antibiotics in the second and third trimester
can be explained by urinary tract infections, a complication in
pregnancy for which treatment is recommended. The high
prescription rate of antibiotics after pregnancy is most likely
caused by infections of the breast and uterus. Because anti-
biotics are also frequently prescribed outside pregnancy, we
decided to categorise antibiotics as drugs for occasional and
short-time use.
The proportion of class A drugs prescribed during preg-
nancy is somewhat lower than the proportion found in an
other study conducted with the IADB (81.7 versus 86%).6
This difference can be explained because we restricted our
analysis to the drugs that were ordered into the three cate-
gories (65.7% of all drugs). In the previous study of the
IADB, all drugs were included. The proportion of category
A drugs in our study is much higher than found in a Danish
study, where 40.9% of all prescriptions during pregnancy
were classified as safe (A).22 We found that 2.4% of all drugs
prescribed in the first trimester were harmful drugs. The
harmful drugs prescribed in the first trimester for pregnancy-
related symptoms were ovulation-stimulating drugs, and for
chronic conditions, antiepileptics. Doxycycline, a tetracycline
antibiotic, was responsible for the high percentage of harmful
drugs for occasional use in the first trimester. Doxycycline
may affect the bone and tooth development of the developing
fetus and is therefore contraindicated in pregnancy.
The strength of our study was that for all women included
in this study, complete data were available on drugs pre-
scribed in the period from 2 years before pregnancy until 3
months after delivery. Because we applied a cohort design
comparing the prescription rates during pregnancy with the
prescription rates before pregnancy in the same population,
selection bias is minimised. Some drug-utilisation studies
compare drug use among pregnant women with drug use
among nonpregnant women of comparable age. This might
introduce bias, since factors related to pregnancy and drug
use might be disproportionately present in the two groups. A
Finnish study showed that more nonpregnant women had
a chronic disease such as epilepsy, rheumatoid diseases, dia-
betes, hypertension, ulcerative colitis and psychotic and men-
tal disorders when compared with pregnant women of
comparable age.17
By distinguishing drugs based on their indication, we could
demonstrate that the increase in prescription rate during
pregnancy is caused by an enhanced prescribing of drugs
for pregnancy-related symptoms. Most other drug-utilisation
studies that investigated drug-use patterns among pregnant
women make no distinction between the indications for
drug use.
Although our study was conducted with data from a
population-based prescription database, only women with
a liveborn child are included. Women with a spontaneous
or induced abortion and women whose pregnancy resulted
in a stillbirth or whose child did not survive until the first
prescription were not included.
Since we have no information on the actual length of
the gestation period, the time of conception was estimated
Bakker et al.
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as 273 days (39 weeks) before birth. The use of a standard
gestational period, mostly 270 days, is common in studies
using administrative data.4,17,18 A recent study, comparing
administrative data with data from a birth registry, showed
that gestational age assumptions can result in a small pro-
portion of misclassification. The extent of potential drug-
exposure misclassification was larger for category X drugs in
the first trimester of pregnancy.23 We believe that administra-
tive datasets with estimated gestational age can be useful in
research on prescription of drugs during pregnancy. How-
ever, in studies evaluating the risk of drugs on birth outcome,
precise timing of drug exposure is essential and then admin-
istrative datasets alone are insufficient.
In our study, ovulation-stimulating drugs were prescribed
in the first trimester of pregnancy, an indication that mis-
classification has occurred. Prescription of other harmful
drugs in the first trimester can also be explained by unaware-
ness of the pregnancy. Although almost 80% of the preg-
nancies in the Netherlands are planned, a woman mostly
does not recognise her pregnancy until the third week after
conception.
The prescription rate as defined in this study reflects the
prescribing behaviour of physicians and cannot be translated
directly into exposure rates. Drugs prescribed for a longer
period of time can lead to an underestimation of exposure
in the subsequent trimesters. Also, particularly in pregnancy,
prescribed drugs are not always taken, leading to overestima-
tion of drug exposure. In a Danish study, only 43% of all
drugs dispensed to pregnant women were reported to be
taken. Compliance was high for drugs used in chronic dis-
eases but low for drugs used for local or short-time treat-
ment.24 Furthermore, the prescription database does not
include drugs administered in hospitals and OTC drugs.
For some drugs, underestimation of exposure may be consid-
erable. The prescription rate of analgesics and antipyretics, for
instance, is very low, with approximately 1.5 per 100 women
during pregnancy. The number of women who used analge-
sics during pregnancy is probably much higher because anal-
gesics are freely available in the Netherlands. In a recent study
in the USA, where data on maternal drug use were evaluated
from two case–control studies of birth defects, at least 65%
of the women took paracetamol at some point during preg-
nancy.25 Other pregnancy-related drugs such as antacids, lax-
atives, folic acid and some antiemetics are also available as
OTC drugs in the Netherlands.
Although not all drugs prescribed to the study population
were ordered into the three categories, we believe that this
study is representative for drugs prescribed to pregnant
women. The drugs included in the three categories accounted
for almost 90% of all prescriptions in the pregnancy period.
Drugs not included in the analyses were rarely prescribed.
The use of population-based prescription databases is an
important tool to monitor the use of drugs among pregnant
women to identify problems. In addition, this individual-level
exposure data can serve as a reference for future risk-assessment
studies and provide relevant information for education
programmes of health professionals as well as for prevention.
Although drug use during pregnancy is mostly studied in
relation to the occurrence of congenital anomalies at birth,
other adverse long-term effects in the offspring, such as devel-
opmental delay, may also be associated with maternal drug
use in the second and third trimester. In a cohort study in
the South West of England, frequent paracetamol use in late
pregnancy was associated with an increased risk of wheezing
in the offspring at 30–42 months.26 If maternal drug use can
be linked to the prescription of drugs to their children,
prescription databases may also be used to screen for certain
long-term drug effects.
In conclusion, this register-based study shows that the
majority of the Dutch women use drugs during pregnancy.
The increase in prescription rate during pregnancy is caused
by an increase in prescription rate for drugs used for pregnancy-
related symptoms, whereas the prescription rate for drugs for
chronic diseases and for occasional and short-time use
declines during pregnancy. Also, the prescription of harmful
drugs decreases during pregnancy. However, 2.3% of all drugs
prescribed for occasional and short-time use in the first tri-
mester were classified as harmful. Therefore, the results of this
study argue in favour for a cautious prescribing of drugs to
healthy women in the fertile age, in which the prescription of
harmful drugs should be avoided as much as possible.
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Appendix 1. Prescription rate per 100 women per trimester* and the results of the chi-square test for trend for all drugs and for the drugs
ordered into the three categories
Trimester x2 test for trend
Total period Pregnancy
28 27 26 25 24 23 22 21 1 2 3 4 x2 P Slope x2 P Slope
All drugs 43.0 43.4 43.3 44.0 44.2 43.0 43.2 43.3 43.6 49.3 60.8 68.0 873.218 0.000 / 320.495 0.000 /
I: Drugs for chronic diseases
Drugs used in diabetes (A10) 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.6 0.4 2.126 0.145 1.695 0.193
Corticosteroids, dermatological (D07) 4.7 5.1 4.7 5.1 5.1 4.9 5.2 2.7 3.9 3.6 3.4 4.7 29.701 0.000 \ 1.400 0.237
Corticosteroids, systemic (H02) 0.8 0.7 0.8 0.8 0.8 0.7 0.9 0.7 0.4 0.4 0.4 0.6 14.823 0.000 \ 0.000 1.000
Thyroid therapy (H03) 0.7 0.7 0.7 0.8 0.8 0.8 1.0 0.9 0.9 0.9 0.9 1.0 4.930 0.026 / 0.000 1.000
Anti-inflammatory and antirheumatic
drugs (M01)
6.2 6.4 7.1 7.2 7.4 7.1 7.4 6.7 2.2 0.7 0.3 5.0 407.643 0.000 \ 86.643 0.000 \
Antimigraine medication (N02C) 0.8 1.0 0.9 1.0 1.0 0.9 1.0 0.8 0.3 0.0 0.0 0.6 72.332 0.000 \ 25.607 0.000 \
Antiepileptics (N03A) 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.3 0.2 0.3 1.844 0.174 0.150 0.698
Antipsychotics and antidepressants
(N05A, excl. N05AB04; N06A)
3.0 3.0 2.9 3.1 3.0 2.9 3.2 2.6 1.9 1.0 0.9 2.1 107.641 0.000 \ 17.374 0.000 \
Antiasthmatics (R03) 2.4 2.9 2.7 2.9 2.9 2.6 2.6 2.6 2.4 2.4 2.3 2.1 9.788 0.002 \ 0.145 0.704
II: Drugs for short-time and occasional use
Antispasmodic and anticholinergic agents and
propulsives (A03, excl. A03FA01)




0.6 0.7 0.7 0.7 0.7 0.6 0.7 0.6 0.6 0.5 0.6 1.9 16.933 0.000 / 0.017 0.897
Antifungals for dermatological use (D01) 2.6 2.3 2.4 2.7 2.1 2.4 2.4 2.1 2.6 2.9 3.2 4.7 44.349 0.000 / 3.579 0.059
Emollients and protectives (D02) 2.0 2.3 1.9 2.0 2.1 1.6 2.0 1.7 2.1 2.3 2.2 2.7 4.457 0.035 / 0.276 0.599
Antibiotics and chemotherapeutics for
dermatological use (D06)
1.3 1.4 1.1 1.1 1.0 1.0 1.0 1.0 0.8 0.7 0.6 1.2 16.963 0.000 \ 0.644 0.422
Antiacne preparations (D10) 1.3 1.4 1.1 1.1 1.0 1.0 1.0 1.0 0.8 0.7 0.6 1.2 9.940 0.002 \ 6.557 0.010 \
Antibacterials for systemic use (J01) 8.2 8.0 8.5 8.2 9.0 8.2 7.9 8.1 6.3 7.3 8.8 13.3 19.427 0.000 / 24.448 0.000 /
Analgesics and antipyretics (N02B) 2.4 2.5 2.7 2.1 2.1 2.1 2.0 2.1 1.4 1.1 1.1 1.6 69.431 0.000 \ 1.743 0.187
Anxiolytics, hypnotics and sedatives
(N05B, N05C)
2.7 2.9 2.5 2.9 3.2 3.0 2.9 2.6 1.2 0.9 1.5 2.4 66.673 0.000 \ 1.797 0.180
Antiparasitic products, insecticides
and repellents (P)
0.7 0.7 0.6 1.0 0.9 0.8 0.9 0.7 0.2 0.1 0.3 0.7 22.614 0.000 \ 1.074 0.300
Antihistamines for systemic use
(R06, excl. R06AD and R06AE)
2.2 2.2 1.7 1.9 1.8 2.3 2.2 1.8 1.0 0.4 0.3 1.2 109.604 0.000 \ 20.800 0.000 \
Ear, eye, nose and throat preparations
(S02, S03, S01, R01, R02A, R05)
6.9 6.7 6.9 7.6 6.9 6.5 6.9 6.4 5.2 5.2 4.8 5.2 63.942 0.000 \ 1.111 0.292
III: Drugs for pregnancy-related symptoms
Antacids (A02A) 1.1 0.9 0.6 0.5 0.5 0.4 0.5 0.6 2.1 8.5 16.7 0.5 1533.455 0.000 / 692.835 0.000 /
Antiemetics (A03FA01, A04A,
N05AB04, R06AD, R06AE)
1.3 1.4 1.6 1.4 1.0 1.3 1.3 1.4 5.8 2.0 1.1 0.8 24.677 0.000 / 208.959 0.000 \
Laxatives (A06) 1.5 1.8 1.3 1.3 1.3 1.5 1.2 1.5 2.4 2.9 2.8 6.9 334.565 0.000 / 2.018 0.155
Iron preparations (B03A) 3.2 2.4 1.8 1.5 1.2 1.1 1.2 1.3 5.2 21.0 31.5 30.4 6638.584 0.000 / 1208.418 0.000 /
Folic acid and derivatives (B03B) 1.2 1.5 1.6 2.0 2.4 3.1 4.1 6.1 8.6 3.5 4.7 5.2 460.647 0.000 / 79.302 0.000 \
Gynaecological anti-infectives and
antiseptics (G01)
2.6 2.5 2.8 2.7 2.5 2.5 2.7 2.7 3.6 6.5 7.2 2.6 168.624 0.000 / 67.139 0.000 /
Gonadotrophins and other ovulation
stimulants (G03G)
0.9 1.0 1.3 1.5 1.9 2.5 2.8 4.2 2.4 0.1 0.1 0.0 25.649 0.000 \ 168.553 0.000 \
*Trimester 28 to 25 represents the second year before pregnancy, trimester 24 to 21 represents the first year before pregnancy. Trimester 1–3 is
the pregnancy period and trimester 4 is the period after pregnancy.
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Appendix 2. Total number of prescription drugs per trimester* and the distribution of these drugs according to the risk classification (only
the prescribed drugs that were categorised into drugs for chronic conditions, drugs for occasional use and drugs for pregnancy-related
symptoms were included)
Trimester
28 27 26 25 24 23 22 21 1 2 3 4
Drugs for chronic diseases
Total number of prescription drugs 1052 1133 1120 1174 1174 1131 1162 1062 701 536 520 919
Proportion (%) classified as
A 36.7 38.0 36.2 35.7 36.8 35.9 37.5 36.7 50.4 62.9 67.5 41.8
B 14.5 15.5 14.0 15.5 14.3 15.5 14.1 15.2 17.1 17.4 16.0 13.7
C 46.7 44.5 48.0 47.1 47.4 46.8 47.0 47.1 30.8 17.5 14.6 42.3
D (1X) 2.1 1.9 1.8 1.7 1.4 1.9 1.4 1.0 1.7 2.2 1.9 2.2
Drugs for short-time and occasional use
Total number of prescription drugs 1632 1628 1587 1651 1636 1553 1573 1497 1166 1109 1186 1805
Proportion (%) classified as
A 47.9 45.9 48.3 47.6 46.5 45.7 45.5 49.9 60.8 75.1 72.2 58.1
B 32.2 34.3 32.0 33.6 32.4 34.3 35.5 31.5 29.1 18.8 19.4 31.2
C 12.5 13.0 11.8 11.8 12.9 13.1 12.1 12.6 7.8 5.5 8.0 8.6
D (1X) 7.4 6.7 7.9 7.1 8.2 6.9 6.9 5.9 2.3 0.5 0.4 2.1
Drugs for pregnancy-related symptoms
Total number of prescription drugs 593 573 588 570 594 659 748 975 1433 1913 2612 2051
Proportion (%) classified as
A 83.0 80.6 77.7 76.7 75.1 73.0 72.1 72.4 89.2 97.6 97.6 95.3
B 11.6 14.7 17.3 18.8 18.7 20.3 21.0 18.5 5.9 1.2 1.3 3.7
C 3.4 3.5 2.7 2.6 1.9 1.8 2.1 1.5 2.1 1.0 1.0 1.0
D (1X) 2.0 1.2 2.2 1.9 4.4 4.9 4.8 7.6 2.9 0.2 0.1 0.0
*Trimester 28 to 25 represents the second year before pregnancy, trimester 24 to 21 represents the first year before pregnancy. Trimester 1–3
is the pregnancy period and trimester 4 is the period after pregnancy.
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